Thirty Years Of Progress. Future Full Of Possibility

Centre for Eye Research Australia

For more than 30 years, Professor Keith Martin has been driven by a simple goal: to give more people the chance to keep their sight. Today, as CERA's Managing Director, he is building on that commitment, leading groundbreaking research and helping shape a future where vision loss and blindness no longer define people's lives.

Throughout his career, from medical student and scientist in the United Kingdom to becoming one of Australia's leading ophthalmology researchers, Professor Martin has focused on one of the leading causes of irreversible blindness worldwide: glaucoma. His research works towards protecting and regenerating the optic nerve, which is the critical link between the eye and the brain that's damaged by the disease.

"I trained as a neuroscientist as well as an ophthalmologist and became fascinated by the eye as part of the brain. I remain excited by trying to figure out how we protect the nerve cells lost in glaucoma, and perhaps one day replace them," he says.

"I was drawn to the precision of eye surgery, but also to the difference it can make to someone's life."

From distant dream to clinical reality

"Thirty years ago, glaucoma treatment was almost entirely focused on lowering eye pressure. We had no therapies that directly protected the optic nerve, and the idea of restoring lost vision felt like a distant dream," says Professor Martin.

He became the first researcher in the world to demonstrate that both gene and stem cell therapy could reduce retinal ganglion cell death in experimental models of glaucoma. These discoveries helped establish entirely new avenues for treatment and laid the foundation for therapies now progressing towards human clinical trials.

"Today, our understanding of glaucoma has advanced dramatically. We now know much more about why the nerve cells connecting the eye to the brain die, and treatments such as gene therapies designed to protect these cells are already progressing into clinical trials," he says.

What gives Professor Martin hope is seeing how far the field has come.

"I see reasons for hope in the clinic and in the lab. Patients give their time to research in the hope of helping others.

"Young researchers bring ideas I would never have thought of myself. And some approaches we once discussed as distant possibilities are now entering clinical trials.

"That is encouraging, even when progress takes longer than we would like," he says.

Bringing global expertise to CERA

In 2019, Professor Martin relocated to Melbourne to become Managing Director of CERA.

Under his leadership, CERA has expanded its research capabilities, strengthened international collaborations and increased its focus on developing new and innovative treatments.

A culture of innovation has also emerged, leading to new spin-out companies focused on developing sight saving therapies and earlier disease detection technologies that aim to improve the lives of people affected by vision loss.

"CERA has all the ingredients needed to be a global leader in eye research," Professor Martin says.

"We have world class scientists, outstanding clinician researchers and a clear focus on delivering outcomes that improve people's lives."

Driving progress together

Reflecting on how far the field has come since CERA was founded 30 years ago, Professor Martin says the change has been remarkable.

"Thirty years ago, many eye diseases that cause blindness were poorly understood and often untreatable. We had fewer tools to diagnose disease, limited treatment options and little understanding of the genetics behind vision loss."

Today, the landscape looks very different.

"We can now detect disease earlier, understand it more deeply, and explore treatments such as gene and cell therapies that were once only possibilities. Research is also more collaborative, with patients, clinicians and scientists working together to drive progress," he says.

"People with eye conditions who now take part in research, also help decide what we study and how we study it," he says.

"At CERA, consumer research partners help us understand what matters in daily life, what makes a trial manageable, and whether the outcomes we measure are the ones patients care about."

"We need that perspective. We also need clinicians, other organisations and supporters alongside us. A discovery in the lab only makes a difference if we can develop it, test it and make it available to the people who need it."

The impossible is now possible

Thanks to decades of research, possibilities that once seemed impossible are becoming reality.

"I do not accept that vision loss is inevitable, even for conditions that, for much of my career, have been untreatable. That is the attitude that drives us at CERA. I am impatient for progress because every year matters to people with vision loss and their families," he says.

"And it's from the support of our donors that gives us the chance to keep going when a promising idea needs years of careful work. Research does not always move quickly, but the possibilities have changed enormously during my career. Donors and supporters help us turn those possibilities into something we can test and, I hope, one day offer to patients."

For the thousands of Australians living with vision loss, every advance brings renewed hope. For Professor Keith Martin, helping transform that hope into reality remains both a deeply personal commitment and a powerful motivation to keep looking to the future.

"I have operated on children with congenital glaucoma as well as very many older people who would have inevitably gone blind without surgery. Knowing that treatment may help someone keep their sight for life stays with me," he says.

Read 30 days of stories, milestones, breakthroughs and reflections from the people who have shaped our journey and those building its future.

Watch Professor Keith Martin present the 14th Gerard Crock Lecture on the transformational technologies CERA is using to beat blindness.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.